Hanna Kirollos
M Health Fairview and Mayo Clinic College of Medicine, Maple Grove, Minnesota.
J Adv Pract Oncol. 2022 Apr;13(3):282-285. doi: 10.6004/Jadpro.2022.13.3.20. Epub 2022 May 23.
During JADPRO Live Virtual 2021, Kirollos Hanna, PharmD, BCPS, BCOP, discussed the label indications of drugs and biologics in hematologic malignancies approved from late 2020 to late 2021, including mechanisms of action and various safety profiles so advanced practitioners can manage and treat patients safely with these new and approved therapeutic agents. In particular, CAR T-cell therapies were approved across many hematologic malignancies, along with PI3K inhibitors, anti-CD38 monoclonal antibodies, and immunotherapies.
在2021年JADPRO现场虚拟会议期间，药学博士、BCPS（认证化疗药学专家）、BCOP（认证肿瘤药学专家）基罗洛斯·汉纳讨论了2020年末至2021年末获批用于血液系统恶性肿瘤的药物和生物制品的标签适应症，包括作用机制和各种安全性概况，以便高级从业者能够安全地使用这些新的获批治疗药物来管理和治疗患者。特别是，CAR-T细胞疗法以及PI3K抑制剂、抗CD38单克隆抗体和免疫疗法在多种血液系统恶性肿瘤中获得批准。
